Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clementia Pharmaceuticals Inc (CMTA)

Clementia Pharmaceuticals Inc (CMTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,002,854
  • Shares Outstanding, K 38,059
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,130 K
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.51
  • Low Estimate -0.54
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.75 +2.33%
on 03/19/19
26.73 -1.42%
on 04/15/19
+0.45 (+1.74%)
since 03/15/19
3-Month
12.18 +116.34%
on 01/28/19
26.73 -1.42%
on 04/15/19
+12.44 (+89.43%)
since 01/17/19
52-Week
8.10 +225.31%
on 08/07/18
26.73 -1.42%
on 04/15/19
+10.05 (+61.66%)
since 04/17/18

Most Recent Stories

More News
Francois Nader, M.D., Joins Moderna's Board of Directors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...

SHPG : 179.20 (+4.10%)
MRNA : 18.87 (+0.48%)
TAK : 20.25 (+1.00%)
SNY : 48.09 (+6.16%)
XLRN : 50.46 (+1.08%)
PRVL : 15.53 (+1.37%)
ALXN : 111.20 (-1.14%)
AAAP : 81.63 (+0.16%)
BXLT : 46.02 (-0.39%)
CMTA : 26.35 (-0.11%)
TRVN : 0.72 (unch)
NOVN : 2.21 (-1.34%)
AZN : 47.98 (+0.44%)
MRK : 89.10 (+0.43%)
Repare Therapeutics Appoints Steve Forte as CFO and Samarth Kulkarni to Its Board of Directors

Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations,...

CRSP : 67.63 (+0.27%)
CMTA : 26.35 (-0.11%)
Retinoic Acid Receptor Gamma Market Size, Share 2019 Industry Trends, Growth Insight, Market Drivers Share, Competitive Analysis, Statistics, Regional, And Global Industry Forecast To 2025

Retinoic Acid Receptor Gamma Market 2019 Report offers a professional and in-depth study on the current state of the Global Retinoic Acid Receptor Gamma Market along with competitive landscape, Retinoic...

CMTA : 26.35 (-0.11%)
PPGNY : 0.0097 (-96.54%)
VRX.TO : 30.80 (-3.33%)
Solid Year for Corporate R&D Spending - Research Infosource

Canada's Top 100 Corporate R&D Spenders recorded a strong 10.6% gain in their combined research spending in Fiscal 2018, compared with an increase of 4.3% in Fiscal 2017. The leading research companies...

BDRAF : 1.4800 (-0.30%)
CMTA : 26.35 (-0.11%)
MGA : 53.65 (+0.73%)
TSG : 24.19 (+0.79%)
SU : 31.82 (+0.16%)
TITXF : 0.1930 (-1.03%)
Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Clarissa Desjardins,...

CMTA : 26.35 (-0.11%)
INSM : 23.29 (+1.66%)
Retinoic Acid Receptor Gamma Market Size, Business Growth, Sales Revenue, Development Status and Forecast 2026

In 2018, the Retinoic Acid Receptor Gamma Market revenue was around US$ XX Mn and the Market share was XX%, and it will be projected to reach US$ XX Mn and XX% in 2026, with a CAGR XX% during the forecast...

CMTA : 26.35 (-0.11%)
PPGNY : 0.0097 (-96.54%)
VRX.TO : 30.80 (-3.33%)
Accomplished Financial Executive, Steve Forte, Joins Profound Medical's Board

Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) ("Profound" or the "Company"), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging ("MRI"),...

PRFMF : 0.7120 (+6.99%)
CMTA : 26.35 (-0.11%)
Global Retinoic Acid Receptor Gamma Market Insights, Forecast to 2019 Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

The market size of Retinoic Acid Receptor Gamma is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will...

CMTA : 26.35 (-0.11%)
PPGNY : 0.0097 (-96.54%)
VRX.TO : 30.80 (-3.33%)
Ipsen Completes Acquisition of Clementia Pharmaceuticals

--Transaction reinforces Ipsen's strong commitment to providing life-altering treatments to patients with high unmet medical needs

CMTA : 26.35 (-0.11%)
IPN : 34.71 (-0.54%)
IPSEY : 22.2000 (+0.50%)
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Quebec Superior Court issued earlier today a final order approving the previously announced...

CMTA : 26.35 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CMTA with:

Business Summary

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company's lead product consists of palovarotene, a novel RAR' agonist, to treat fibrodysplasia ossificans progressiva,...

See More

Key Turning Points

2nd Resistance Point 26.85
1st Resistance Point 26.60
Last Price 26.35
1st Support Level 26.19
2nd Support Level 26.03

See More

52-Week High 26.73
Last Price 26.35
Fibonacci 61.8% 19.61
Fibonacci 50% 17.42
Fibonacci 38.2% 15.22
52-Week Low 8.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar